♦ Aims: We investigated dialysis duration, dose of erythropoietin (EPO), and clinical manifestations in peritoneal dialysis (PD) patients with subclinical hypothyroidism. ♦ Methods: This cross-sectional study, performed in 3 centers, assessed 122 adult patients on PD for more than 6 months with regard to demographic data, dialysis duration, thyroid function, biochemical data, EPO dose, and clinical manifestations. Thyroid dysfunction was determined by serum thyroid-stimulating hormone, free thyroxine, total thyroxine, total triiodothyronine, antithyroid peroxidase antibodies, and auto-antibodies against thyroglobulin. ♦ Results: Of the 122 study patients, 98 (80.3%) were assessed as having euthyroidism; 19 (15.6%), subclinical hypothyroidism; and 5 (4.1%), subclinical hyperthyroidism. The proportion of women (74.2% vs. 57.1%, p = 0.038), the mean duration of PD (58.1 months vs. 37.9 months, p = 0.032), and the weighted mean monthly EPO dose (1.22 μg/kg vs. 1.64 μg/kg, p = 0.009 ) were significantly higher in the subclinical hypothyroidism group than in the euthyroidism group, but the prevalences of coronary artery disease and cerebrovascular disease were not. From the multivariate model, PD duration was more significant than sex as a risk factor for subclinical hypothyroidism (p = 0.0132). ♦ Conclusions: Subclinical hypothyroidism is frequent in PD patients, especially female patients and patients with a longer PD duration. Compared with euthyroid patients, patients with subclinical hyperthyroidism need a higher dose of EPO to maintain a stable hemoglobin level.
T hyroid dysfunction affects a significant portion of the general population (1-4) and of patients with renal failure (5) (6) (7) (8) (9) (10) . Thyroid function is reported to be abnormal in many patients once renal function declines below 50% (5, 11) . Subclinical hypothyroidism in dialysis patients has been reported to be causally related to the retention of excess iodide, to protein loss from dialysate, and to uremic toxins (5, (12) (13) (14) (15) (16) (17) . Whether subclinical hypothyroidism is associated with the duration of peritoneal dialysis (PD) or with erythropoietin (EPO) dose is seldom investigated.
Subclinical hypothyroidism has been reported to be associated with cardiovascular disease (18) (19) (20) (21) (22) and cerebrovascular disease (23) (24) in the general population. Coronary artery disease (CAD) and cerebrovascular disease are also associated with end-stage renal disease (25) (26) (27) (28) (29) . Whether subclinical hypothyroidism is associated with these diseases in patients on PD is not well defined. Our study therefore investigated the associations of dialysis duration, EPO dose, and clinical manifestations such as CAD and cerebrovascular disease with subclinical hypothyroidism in PD patients.
METHODS

PARTICIPANTS
The study recruited 137 patients 18 years or older who had been treated with 3 or 4 daily 2-L exchanges of glucose-containing standard dialysate for more than 6 months at 3 in-hospital dialysis units in northern Taiwan patients also had to have been free of peritonitis for at least 6 months. Weekly Kt/V was at least 1.7.
To avoid misinterpretation of treatment response to EPO, patients with other causes of poor response to EPO therapy-such as malignancy, liver cirrhosis, thalassemia, iron deficiency, gastrointestinal bleeding, or a major operation within the 6 months preceding the thyroid function evaluation-were excluded. Patients with a pre-existing diagnosis of thyroid disease were not excluded from the study.
The 122 patients who met the inclusion criteria (Figure 1 ) all provided written informed consent. The study protocol was approved by the institutional review board of Taipei Veterans General Hospital and was performed in accordance with the ethical principles of the Declaration of Helsinki.
BLOOD SAMPLES AND LABORATORY DATA
For the sake of reliability, venous blood samples were drawn at each participating site and were then sent to the central laboratory at Taipei Veterans General Hospital for measurement of serum thyroid-stimulating hormone (TSH), antithyroid peroxidase antibodies (anti-TPO), auto-antibodies against thyroglobulin (anti-TG), free thyroxine (FT 4 ), total thyroxine (T 4 ), and total triiodothyronine (T 3 ). Levels of TSH, anti-TPO, and anti-TG were measured by chemiluminescent immunometric assay (DPC Immulite 2000: Seracon Diagnostics, Brownsville, TX, USA). Levels of FT 4 , T 4 , and T 3 were measured by a chemiluminescent competitive analog immunoassay (DPC Immulite 2000). In Taiwan, each PD patient undergoes a routine monthly biochemistry profile that includes blood urea nitrogen; serum levels of creatinine, sodium, potassium, bicarbonate, albumin, cholesterol, triglycerides, uric acid, calcium, phosphate, glucose, intact parathyroid hormone, and hemoglobin; and efficacy of dialysis (demonstrated by Kt/V). Data for the foregoing variables were therefore available for a 6-month period preceding the thyroid function test. For each patient, the study analysis used the mean of those monthly values. PERSONAL 
DATA
Demographic data for the patients (age, sex, body weight, height, date of PD) were collected from each participating site. Any history of diabetes mellitus, thyroid diseases, upper gastrointestinal bleeding, major operation, malignancy, liver cirrhosis, and treatment with EPO over the 6-month period preceding the thyroid function test was also recorded at each participating site and was sent to Taipei Veterans General Hospital. Comorbid conditions, including underlying CAD and cerebrovascular disease, were also recorded. We defined CAD and cerebrovascular disease as any hospital admission with a diagnosis of coronary disease or cerebrovascular accident .
DEFINITIONS OF EUTHYROIDISM AND SUBCLINICAL HYPOTHYROIDISM
Reference ranges for the biochemical variables of interest are these: TSH, 0.4 -4 μIU/mL; FT4, 0.8 -1.9 ng/ dL; T3, 72 -170 ng/dL; T4, 4.5 -12.5 μg/dL; anti-TPO, <35 IU/mL; and anti-TG, <40 IU/mL. Hypothyroidism was defined as TSH > 4 μIU/mL and FT4 < 0.8 ng/dL. Subclinical hypothyroidism was defined as TSH > 4 μIU/ mL and normal FT4. Hyperthyroidism was defined as TSH < 0.4 μIU/mL and T3 > 170 ng/dL or T4 > 12.5 μg/dL. Subclinical hyperthyroidism was defined as TSH < 0.4 μIU/ mL and normal FT4. Patients with normal levels of TSH and FT4, but receiving treatment with thyroxine were categorized as having euthyroidism.
STATISTICAL ANALYSIS
Data were analyzed using the SPSS software application (release 13.0: SPSS, Chicago, IL, USA) for Windows (Microsoft, Redmond, WA, USA). The prevalences of thyroid disease are shown as frequencies. Because of the small number of cases of subclinical hyperthyroidism (only 5), those cases were not analyzed any further in the study. Chi-square and two-sample t-tests were conducted to test the differences between the euthyroidism and subclinical hypothyroidism groups. A p value less than 0.05 indicated statistical significance. Stepwise logistic regression models were used to assess associations of risk factors in the subclinical hypothyroidism group.
RESULTS
PREVALENCE OF THYROID DYSFUNCTION
In this study, no patient was diagnosed with hypothyroidism or hyperthyroidism. After thyroid function testing, 98 of the 122 PD patients (80.3%) were defined as having euthyroidism; 19 (15.6%), subclinical hypothyroidism; and 5 (4.1%), subclinical hyperthyroidism ( Figure 1 ). Of the 98 patients with euthyroidism, 2 (2.04%) had previously been diagnosed with hypothyroidism, and of the 19 patients with subclinical hypothyroidism, 1 (5.26%) had previously been diagnosed with hyperthyroidism (Table 1 ). The 2 patients with previous hypothyroidism were taking levothyroxine sodium (50 μg daily and 100 μg daily). The 1 patient with previous hyperthyroidism had undergone subtotal thyroidectomy and was not on medical treatment with levothyroxine sodium.
After exclusion of the 5 patients with subclinical hyperthyroidism, 117 patients [72 women (61.5%), 45 men (38.5%); 27 (23.1%) with diabetes mellitus; 15 (12.8%) over 65 years of age] remained for further analysis (Table 2) .
COMPARISON BETWEEN THE EUTHYROIDISM AND SUBCLINICAL HYPOTHYROIDISM GROUPS
Compared with the euthyroidism group, the subclinical hypothyroidism group had a significantly higher TSH level (2.07 ± 0.94 μIU/mL vs. 5.97 ± 2.16 μIU/mL, p < 0.001), (2, 32) . Because women tend to have a lower body weight compared with body weight in men, the higher proportion of women in the subclinical hypothyroidism group may also explain the overall lower body weight and body mass index in that group (Table 2 ).
In the general population, the presence of antithyroid antibodies has been the most frequent cause of subclinical hypothyroidism [54% -67% (2)]; but in PD patients with subclinical hypothyroidism, the prevalences of anti-TPO and anti-TG antibodies are low: 15.8% and 10.5% respectively in the present study, similar to rates in previous reports (30, 33) . The inconsistency in the causes of subclinical hypothyroidism in the general population and in PD patients was not clearly understood in the past. Impaired immunity in end-stage renal disease patients is not improved by maintenance dialysis (34, 35) , and therefore antibody titers continue to be low, and the response rate to vaccinations for viral hepatitis, tetanus, and diphtheria, poor (36, 37) . We therefore hypothesized that the inconsistency in the prevalence of antithyroid antibodies between subclinical hypothyroidism in the general population and in PD patients may be partly attributable to the impaired immune function in dialysis patients. On the other hand, the low prevalence of antithyroid antibodies in dialysis patients also supports suggestions in previous reports that the substantial number of dialysis patients with subclinical hypothyroidism may be related to retention of excess iodide, to protein loss from dialysate, or to uremic toxins rather than to autoimmune mechanisms (5, (12) (13) (14) (15) (16) (17) . The longer PD duration in the subclinical hypothyroidism group might also support a suggestion of iodide retention or an effect of uremic toxins (Table 2) .
When PD duration and the interaction of age with PD duration were added into the stepwise logistic regression model, PD duration was more significant than sex as a risk factor for subclinical hypothyroidism (Table 3) . Patients with a longer PD duration also had longer retention of excess iodide and uremic toxins, possibly also explaining the presence of subclinical hypothyroidism.
Our study also showed a significantly higher weighted mean monthly EPO dose (1.22 μg/kg vs. 1.64 μg/kg, p = 0.009) in the subclinical hypothyroidism group (Table 2) , supporting previous reports that a state of euthyroidism is essential for the action of EPO on bone marrow (38) (39) (40) .
but the other parameters of thyroid function (FT4, T3, T4, anti-TPO, and anti-TG) were not significantly different between the groups. Other parameters-age; presence and duration of diabetes mellitus; body height; blood urea nitrogen; serum levels of creatinine, sodium, potassium, bicarbonate, albumin, cholesterol, triglycerides, uric acid, calcium, phosphate, glucose, intact parathyroid hormone, and hemoglobin; and efficacy of dialysis (Kt/V)-were also not significantly different between the euthyroidism and subclinical hypothyroidism groups. Subclinical hypothyroidism was significantly more prevalent among women than euthyroidism was (84.2% vs. 57.1%, p = 0.038). Mean body weight and body mass index were significantly lower in the subclinical hypothyroidism group than in the euthyroidism group (52.9 ± 7.6 kg vs. 61.7 ± 13.6 kg, p < 0.001). The mean duration of PD (58.1 ± 37.7 months vs. 37.9 ± 37.2 months, p = 0.032), the number of patients on PD for more than 5 years (52.6% vs. 21.4%, p = 0.009), and the weighted mean monthly EPO dose (1.22 μg/kg vs. 1.64 μg/kg, p = 0.009) were significantly higher in the subclinical hypothyroidism group than in the euthyroidism group (Table 2) .
In the euthyroidism group (n = 98), 9 patients (9.2%) had CAD, and 6 (6.1%) had cerebrovascular disease. In the subclinical hypothyroidism group (n = 19), 2 patients had CAD (10.5%), and 1 (5.3%) had cerebrovascular disease. The prevalences of CAD (9.2% vs. 10.5%, p = 0.679) and cerebrovascular disease (6.1% vs. 5.3%, p = 0.999) were not significantly different between the groups (Table 2) .
STEPWISE LOGISTIC REGRESSION MODEL ANALYSIS FOR SUBCLINICAL HYPOTHYROIDISM
In Table 3 , model 1 showed that subclinical hypothyroidism was associated with sex, but not with age, diabetes, or body mass index. Subclinical hypothyroidism occurred in women at a rate 4 times the rate in the overall group [odds ratio (OR) = 4, p = 0.0361]. When PD duration and the interaction of age with PD duration were added into model 1 (as model 2 for further analysis), a dialysis duration longer than 5 years was more significantly associated with subclinical hypothyroidism (OR = 3.74, p = 0.0132) than sex was (OR = 3.62, p = 0.0562).
DISCUSSION
The fact that no study patient was diagnosed with clinical hypothyroidism might be attributable to the low prevalence of this condition in renal failure patients (7) or to the relatively small study population. The substantial proportion of PD patients with subclinical Previous reports showed an association between subclinical hypothyroidism and cerebrovascular diseases (25) (26) (27) and CAD (28, 29) in dialysis patients, but in the present study, the prevalence of such diseases was not significantly different between the euthyroidism and subclinical hypothyroidism groups (Table 2 ). In addition, a cross-sectional analysis by Imaizumi et al. and a population study by Dorr et al. did not find evidence to support subclinical hypothyroidism as a potential risk factor for cerebrovascular disease (18, 41) . A study by Rodondi et al. (42) with a 4-year follow-up showed that subclinical hypothyroidism was not associated with an increased risk for CAD and stroke. In fact, other studies even showed associations of subclinical hypothyroidism with better functional outcomes in patients with ischemic stroke (43) and with good cardiorespiratory fitness (44) , and a possibly protective effect of subclinical hypothyroidism on cardiovascular risk and functional mobility in the elderly (44, 45) . Taken together, findings in the present study and in previous reports suggest that the issue of cerebrovascular and cardiovascular disease risk remains controversial in PD patients with subclinical hypothyroidism. Further large-scale prospective multicenter studies are therefore needed to assess the association of subclinical hypothyroidism with cerebrovascular diseases and CAD in PD patients.
Several methodologic issues should be considered in the interpretation of our results:
• First, ascertainment of cerebrovascular disease and CAD was not possible in all patients. Some patients with non-angina CAD (that is, patients with diabetes) or lacunar infarction, or those who were not willing to undergo confirmatory evaluation during hospital admission, could not be analyzed. Although we found no association between thyroid status and cardiovascular disease in the present study, we cannot draw a definitive conclusion. Being that this is only a crosssectional study, there will be survivor effects, among others. There may be an association, but the present study was not designed to pick it up.
• Second, the onset and duration of subclinical hypothyroidism in the patients could not be unequivocally defined in this study.
• Finally, the sample size is not large enough to avoid the possibility of selection bias.
Despite those limitations, it should be noted that contrary to earlier assumptions, subclinical hypothyroidism may not be associated with cerebrovascular and CAD in PD patients.
CONCLUSIONS
A substantial number of PD patients unknowingly had laboratory evidence of thyroid disease. Subclinical hypothyroidism was common in female PD patients and was associated with longer PD duration. Subclinical hypothyroidism in PD patients contributes to the significantly higher dose of EPO needed to maintain hemoglobin. The relationships between subclinical hypothyroidism and cerebrovascular disease and CAD may need further largescale prospective multicenter studies to delineate. 
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